* Kineta Inc KA.OQ KA.O is expected to show a fall in
quarterly revenue when it reports results on May 10
(estimated).
*
* Refinitiv's mean analyst estimate for Kineta Inc is for a
loss
of 72 cents per share.
* The one available analyst rating on the shares is "buy".
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".
* Wall Street's median 12-month price target for Kineta Inc
is
$8, above its last closing price of $4.26.
This summary was machine generated May 8 at 11:36 GMT. All
figures in US dollars unless otherwise stated